Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent.

[1]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[2]  Deepak L. Bhatt,et al.  Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. , 2017, The Canadian journal of cardiology.

[3]  S. Yusuf,et al.  Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. , 2013, Journal of the American College of Cardiology.

[4]  J. McMurray,et al.  When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches , 2012, Circulation. Heart failure.

[5]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[6]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[7]  Susan Regan,et al.  Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.

[8]  J. Cox,et al.  Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. , 2001, BMJ : British Medical Journal.

[9]  Joanna E Cohen,et al.  Universities and tobacco money , 2001, BMJ : British Medical Journal.

[10]  B. Gage,et al.  The Effect of Stroke and Stroke Prophylaxis With Aspirin or Warfarin on Quality of Life , 1996 .

[11]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.